The Food and Drug Administration (FDA) has given a warning to consumers and drug establishments about the circulation of fake medicine for hepatitis C in Southeast Asia which may reach the Philippine market.
The FDA listed Sofosbuvir+Ledipasvir (Ledso) 400-milligrams/90-mg capsule with batch number 0022, and Daclatasvir (Dakavir) 60-mg capsule with batch number 0322 as the fake hepatitis C drugs that drug outlets and the public should watch out for.
Both drug batches have a manufacturing date of May 2015, an expiration date of April 2017 and are unregistered in FDA.
The World Health Organization (WHO) also issued a health warning, stating that the fake hepatitis C drugs were labeled as manufactured by Pharco Corp. in Alexandria, Egypt. However, Pharco Corp. has denied manufacturing both drug products.
The FDA added that Officers of the Field Regulatory Operations Office has already been deployed to inspect if drug stores and establishments are selling the fake hepatitis C medicine.
The intake of fake medicine such as fake hepatitis c drugs poses serious health risks to the public. These include poisoning, nausea, vomiting, diarrhea, digestive problems, gas perfusion, dyspnea, infection, organ failure, death, abnormal heart function, elevated blood glucose levels, and acceleration of the progression of the disease which can be fatal depending on the person’s health condition.